Article: Genzyme Corp. Wins FDA Panel Approval to Use Seprafilm Product.(Originated from The Boston Globe)

Mar. 26--Genzyme Corp. yesterday won approval for limited use from a U.S. Food and Drug Administration advisory panel for one of its products to reduce postoperative adhesions in gynecological and abdominal surgeries.

The FDA typically follows the panel's recommendation.

While the Cambridge company claimed victory, citing Seprafilm's 5-1 approval, its general division stock plunged as much as 8 before closing down 6 1-4 at 57 1-4 on heavy trading of 4.745 million shares.

The stock drop came before the final vote after early word spread that the FDA panel questioned the benefits of Seprafilm, the first indication the product might receive limited ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!